Online citations, reference lists, and bibliographies.
← Back to Search

Nanodelivery Of Nitazoxanide: Impact On The Metabolism Of Taenia Crassiceps Cysticerci Intracranially Inoculated In Mice.

M. C. Vinaud, D. Real, C. M. Fraga, Nayana F Lima, Ruy De Souza Lino Junior, D. Leonardi, Claudio J Salomon
Published 2020 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Aim: To formulate nanocapsules and nanoemulsions of nitazoxanide (NTZ) and evaluate the metabolic effect on Taenia crassiceps cysticerci inoculated intracranially into mice. Materials & methods: NTZ nanosystems were formulated through solvent diffusion methodology. These nanoformulations were administered perorally and their impact on glycolysis, the tricarboxylic acid cycle and fatty acid metabolism in T. crassiceps cysticerci was investigated. Results: Gluconeogenesis and protein catabolism were significantly increased by the nanoformulations when compared with the control group and the NTZ-treated group. All the other metabolic pathways were inhibited by the nanoformulation treatments. Conclusion: The remarkable metabolic modifications that occur in this in vivo model through the application of these developed nanosystems confirm their capability to deliver NTZ into targeted tissues.
This paper references
10.1016/j.actatropica.2018.12.017
Oral nitazoxanide treatment of experimental neurocysticercosis induces gluconeogenesis in Taenia crassiceps cysticerci.
Nayana F. Lima (2019)
10.1016/j.jconrel.2018.05.031
Sustained therapeutic efficacy of budesonide‐loaded chitosan swellable microparticles after lung delivery: Influence of in vitro release, treatment interval and dose
Lan Zhang (2018)
10.1007/s00436-017-5614-8
In vivo treatment with nitazoxanide induces anaerobic metabolism in experimental intraperitoneal cysticercosis
Joelma M. Nasareth (2017)
10.1079/9780851990279.0387
Unusual aspects of metabolism in flatworm parasites.
A. G. Tielens (2005)
10.1016/j.actatropica.2019.105080
NANOCARRIERS FOR EFFECTIVE DELIVERY OF BENZNIDAZOLE AND NIFURTIMOX IN THE TREATMENT OF CHAGAS DISEASE: A REVIEW.
E. Arrúa (2019)
10.1093/JAC/DKL463
Efficacy of nitazoxanide, tizoxanide and tizoxanide/albendazole sulphoxide combination against Taenia crassiceps cysts.
Francisca Palomares-Alonso (2007)
10.1111/ics.12260
Nanoemulsion: process selection and application in cosmetics – a review
M. N. Yukuyama (2016)
10.1016/j.ijpharm.2015.07.007
Parenteral nanoemulsions as promising carriers for brain delivery of risperidone: Design, characterization and in vivo pharmacokinetic evaluation.
Sanela M. Đorđević (2015)
10.1016/j.ijpharm.2019.118979
Functional ibuprofen-loaded cationic nanoemulsion: development and optimization for dry eye disease treatment.
Bisera Jurišić Dukovski (2019)
10.1080/17425247.2019.1553955
Future of nanomedicines for treating respiratory diseases
R. Scherließ (2019)
10.1016/j.colsurfb.2018.01.019
Chitosan nanoencapsulation of flavonoids enhances their quorum sensing and biofilm formation inhibitory activities against an E.coli Top 10 biosensor.
Eric Omori Omwenga (2018)
10.4269/AJTMH.1997.57.354
Immunoblot with cerebrospinal fluid from patients with neurocysticercosis using antigen from cysticerci of Taenia solium and Taenia crassiceps.
A. Vaz (1997)
10.1016/j.exppara.2009.03.015
Taenia crassiceps: fatty acids oxidation and alternative energy source in in vitro cysticerci exposed to anthelminthic drugs.
M. C. Vinaud (2009)
10.1016/J.EXPPARA.2007.01.013
Taenia crassiceps organic acids detected in cysticerci.
M. C. Vinaud (2007)
10.1016/j.actatropica.2017.02.019
Nanopharmaceuticals as a solution to neglected diseases: Is it possible?
G. A. Islan (2017)
10.1007/s11095-010-0309-1
Nano-emulsions and Micro-emulsions: Clarifications of the Critical Differences
N. Anton (2010)
10.4103/0378-6323.165541
Successful treatment of cutaneous leishmaniasis with nitazoxanide.
A. Dhawan (2015)
10.1016/j.msec.2018.07.050
Praziquantel systems with improved dissolution rate obtained by high pressure homogenization.
M. A. González (2018)
10.1016/j.antiviral.2014.07.014
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
J. Rossignol (2014)
10.1111/j.1365-3024.2010.01231.x
Fact or hypothesis: Taenia crassiceps as a model for Taenia solium, and the S3Pvac vaccine
M. Lightowlers (2010)
10.1016/j.actatropica.2015.08.006
Taenia solium in Europe: Still endemic?
B. Devleesschauwer (2017)
10.4103/0250-474X.89759
Simultaneous Spectrophotometric Estimation of Nitazoxanide and Ofloxacin in Tablets
M. D. Game (2011)
10.1016/j.ijpharm.2009.07.001
Melatonin-loaded lecithin/chitosan nanoparticles: physicochemical characterisation and permeability through Caco-2 cell monolayers.
A. Hafner (2009)
10.4155/tde-2019-0077
Recent advancements in brain tumor targeting using magnetic nanoparticles.
Himanshu Gandhi (2020)
10.1016/j.actatropica.2019.04.013
Evaluation of nitazoxanide as a novel drug for the treatment of acute and chronic toxoplasmosis.
S. El-Kowrany (2019)
10.1016/j.actatropica.2019.04.020
Nano-facilitated drug delivery strategies in the treatment of plasmodium infection.
Nethravathi Puttappa (2019)
10.1016/j.ijantimicag.2019.05.003
Ivermectin: From theory to clinical application.
D. Ashour (2019)
10.1016/j.actatropica.2018.12.012
Overview of Taenia solium cysticercosis in West Africa.
R. Weka (2019)
10.1016/J.IJPHARM.2006.06.036
Formation of self-organized nanoparticles by lecithin/chitosan ionic interaction.
F. Sonvico (2006)
10.1016/j.exppara.2011.11.001
Taenia crassiceps: host treatment alters glycolisis and tricarboxilic acid cycle in cysticerci.
Carolina Miguel Fraga (2012)
10.1039/c6cc00975a
Cocrystals and alloys of nitazoxanide: enhanced pharmacokinetics.
K. Suresh (2016)
10.1128/AAC.00707-18
Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with Ribavirin by Activation of Cellular Antiviral Response
W. Dang (2018)
10.4155/TDE-2016-0038
Biological voyage of solid lipid nanoparticles: a proficient carrier in nanomedicine.
Hasan Ali (2016)
10.1208/s12248-010-9185-1
DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles
Y. Zhang (2010)
10.3389/fmicb.2015.01208
Drug Development Against the Major Diarrhea-Causing Parasites of the Small Intestine, Cryptosporidium and Giardia
Y. Miyamoto (2015)
10.1007/S003960050050
Development of positively charged colloidal drug carriers: Chitosan-coated polyester nanocapsules and submicron-emulsions
P. Calvo (1997)
10.2217/nnm-2018-0139
Nanoparticle crossing of blood-brain barrier: a road to new therapeutic approaches to central nervous system diseases.
V. Ceña (2018)
10.1016/S0378-5173(00)00554-8
Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and -independent methods.
N. Yuksel (2000)
10.1586/14787210.2.1.43
Nitazoxanide: a new broad spectrum antiparasitic agent.
C. White (2004)
10.1016/j.yebeh.2017.03.013
Antiparasitic treatment of neurocysticercosis - The effect of cyst destruction in seizure evolution
H. H. García (2017)
10.1016/j.jiph.2016.04.001
Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
J. Rossignol (2016)
10.1016/S0140-6736(14)61353-2
Of pigs and people—WHO prepares to battle cysticercosis
J. Maurice (2014)
10.1016/S1471-4922(01)02205-X
Treatment of intestinal parasitic infections: a review of nitazoxanide.
H. Gilles (2002)
10.4155/tde-2019-0044
Polymeric nanoparticles as carrier for targeted and controlled delivery of anticancer agents.
Vahid Taghipour-Sabzevar (2019)
10.1093/jac/dkp199
High efficacy of albendazole-PEG 6000 in the treatment of Toxocara canis larva migrans infection.
D. Leonardi (2009)
10.2217/NNM.12.197
Conference Scene: From innovative polymers to advanced nanomedicine: Key challenges, recent progress and future perspectives
J. Feijen (2013)
10.1128/CMR.15.4.747-756.2002
Current Consensus Guidelines for Treatment of Neurocysticercosis
H. García (2002)
10.1016/J.IJID.2007.04.017
Successful treatment of niclosamide- and praziquantel-resistant beef tapeworm infection with nitazoxanide.
Mohammad Lateef (2008)
10.4269/AJTMH.2003.68.382
Nitazoxanide: an important advance in anti-parasitic therapy.
A. White (2003)
10.1590/S0004-282X2012005000010
Experimental encephalitis caused by Taenia crassiceps cysticerci in mice.
Hidelberto Matos-Silva (2012)
10.2165/00003495-200767130-00015
Nitazoxanide: a review of its use in the treatment of gastrointestinal infections.
V. Anderson (2007)
10.1166/JBN.2016.2215
Lipid-Core Nanocapsules Act as a Drug Shuttle Through the Blood Brain Barrier and Reduce Glioblastoma After Intravenous or Oral Administration.
S. F. Rodrigues (2016)
10.1007/s13346-017-0446-8
Finding key nanoprecipitation variables for achieving uniform polymeric nanoparticles using neurofuzzy logic technology
Miguel O. Jara (2017)
10.2174/1872211313666190123153711
Nanocapsules for Drug Delivery: An Updated Review of the Last Decade.
Nazlı Erdoğar (2018)
10.1166/JNN.2010.1920
Nanocapsules prepared from amorphous polyesters: effect on the physicochemical characteristics, drug release, and photostability.
M. Fontana (2010)
10.2147/IJN.S37840
Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability
A. Neves (2013)
10.1371/journal.pone.0207625
Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations
D. Real (2018)
10.3923/JBS.2016.120.127
Nanocapsulation of Nitazoxanide in Solid Lipid Nanoparticles as a New Drug Delivery System and in vitro Release Study
Roghayeh Abbasalipo (2016)
10.4155/fmc.09.170
Towards novel antifilarial drugs: challenges and recent developments.
P. Singh (2010)
10.3390/pharmaceutics9040058
Resveratrol-Loaded Lipid Nanocarriers: Correlation between In Vitro Occlusion Factor and In Vivo Skin Hydrating Effect
L. Montenegro (2017)
10.1016/j.colsurfb.2019.01.039
Development and characterization of benznidazole nano- and microparticles: A new tool for pediatric treatment of Chagas disease?
Katia P. Seremeta (2019)



Semantic Scholar Logo Some data provided by SemanticScholar